Theriva Biologics, Inc. (TOVX) - Dilution Analysis

10-Q filing | 45.9M shares outstanding

10-K filing | 45.9M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time of up to an aggregate of 16,184,560 shares of common stock of Theriva Biologics, Inc. by the Selling Stockholders.

10-Q filing | 9.6M shares outstanding

10-Q filing | 8.2M shares outstanding

8-K filing: Theriva Biologics, Inc. consummated a public offering of 1,990,900 shares of common stock, pre-funded warrants to purchase 4,827,280 shares, and common stock purchase warrants to purchase 6,818,180 shares, for gross proceeds of approximately $7.5 million. ($7.5M proceeds)

S-1/A filing: The company is filing an S-1/A to offer up to 8,403,361 shares of Common Stock and accompanying Common Warrants to purchase up to 8,403,361 shares of Common Stock, or up to 8,403,361 Pre-Funded Warrants to purchase shares of Common Stock and accompanying Common Warrants to purchase up to 8,403,361 shares of Common Stock on a reasonable "best efforts" basis.

10-K filing | 2.8M shares outstanding

S-1/A filing: This S-1/A filing relates to a proposed offering of up to 6,756,756 shares of Common Stock and accompanying Common Warrants or Pre-Funded Warrants and accompanying Common Warrants on a reasonable "best efforts" basis, with the net proceeds intended for working capital and general corporate purposes.

S-1 filing: This S-1 filing describes an offering of common stock and warrants. The company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up.

10-Q filing | 2.8M shares outstanding

8-K filing: Theriva Biologics, Inc. consummated a public offering of 918,600 shares of common stock, pre-funded warrants to purchase up to 510,000 shares of common stock, and common stock purchase warrants to purchase up to 1,428,600 shares of common stock, resulting in gross proceeds of approximately $2.5 million. ($2.5M proceeds)

S-1/A filing: The company is offering up to 2,173,913 shares of common stock, together with warrants to purchase up to 2,173,913 shares of common stock, and pre-funded warrants to purchase up to 2,173,913 shares of common stock underlying the common warrants and pre-funded warrants.

S-3/A filing: Theriva Biologics, Inc. files an S-3/A registration statement to offer and sell up to $200,000,000 of common stock, preferred stock, and/or debt securities.

S-1 filing: This is an S-1 filing for Theriva Biologics, Inc. registering the offering of common stock, pre-funded warrants and common warrants with the intention to use the net proceeds for working capital and general corporate purposes, including for research and development and potential acquisitions.

8-K filing: Theriva Biologics, Inc. received a notice of conversion from the holder of 4,138 shares of its Series C Convertible Preferred Stock and 100,000 shares of its Series D Convertible Preferred Stock which were converted into 27,316 shares of the Company's common stock at a conversion price of $30.50 per share.

8-K filing: Stock split 1-for-25 | Outstanding: 25,131,230 → 1,005,249

10-Q filing | 25.1M shares outstanding

8-K filing: On July 30, 2024, the Company received a notice of conversion from the holder of shares of its Series C Convertible Preferred Stock to convert the 135,431 shares of Series C Convertible Preferred Stock into 888,072 shares of the Company's common stock at a conversion price of $1.22 per share.

8-K filing: Theriva Biologics, Inc. received a notice of conversion of 135,431 shares of its Series C Convertible Preferred Stock into 888,072 shares of the Company's common stock at a conversion price of $1.22 per share on May 13, 2024.

10-Q filing | 17.1M shares outstanding

S-3 filing: Theriva Biologics, Inc. is offering a combination of securities, including common stock, preferred stock, and debt securities, up to a total of $200,000,000, and is also offering common stock through an at-the-market offering.

10-K filing | 16.1M shares outstanding

10-Q filing | 17.0M shares outstanding

10-Q filing | 17.0M shares outstanding

10-Q filing | 15.1M shares outstanding

10-K filing | 15.3M shares outstanding

8-K filing: Theriva Biologics, Inc. repurchased 720,000 shares of its common stock from three founders of its subsidiary for an aggregate purchase price of $288,072. ($0.29M proceeds)

10-Q filing | 15.8M shares outstanding

S-3 filing: The selling stockholder may offer and resell under this prospectus up to 2,459,017 shares of common stock.

10-Q filing | 15.8M shares outstanding

8-K filing: Synthetic Biologics, Inc. closed a private placement offering issuing 275,000 shares of Series C Convertible Preferred Stock and 100,000 shares of Series D Convertible Preferred Stock at $8.00 per share, for gross proceeds of approximately $3.0 million. ($3.0M proceeds)

8-K filing: Stock split 1-for-10 | Outstanding: 158,437,840 → 15

10-Q filing | 158.4M shares outstanding

10-K filing | 158.4M shares outstanding

8-K filing: Synthetic Biologics, Inc. amended its Share Purchase Agreement with VCN Biosciences, S.L. to reallocate a portion of the 26,395,303 shares of common stock to certain key employees and consultants of VCN at the closing of the acquisition of VCN.

8-K filing: Synthetic Biologics, Inc. entered into a Share Purchase Agreement with VCN Biosciences, S.L. to acquire all outstanding shares of VCN in exchange for $4,700,000 and 26,395,303 shares of Synthetic's common stock.

10-Q filing | 132.0M shares outstanding

S-3 filing: This prospectus relates to the offer and sale of 6,344,966 shares of common stock issuable upon the exercise of outstanding warrants that were issued in October 2018, exercisable at $0.69 per share until October 15, 2023.

10-Q filing | 132.0M shares outstanding

10-Q filing | 132.0M shares outstanding

S-3 filing: The company is filing an S-3 to offer and sell up to $300,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings.

8-K filing: Synthetic Biologics, Inc. entered into Amendment No. 1 to the amended and restated at market issuance sales agreement with B. Riley Securities, Inc. and A.G.P./Alliance Global Partners, as sales agents, pursuant to which sales may occur under the Company's New Registration Statement. ($83.6M proceeds)

10-K filing | 129.7M shares outstanding

8-K filing: Synthetic Biologics, Inc. sold 65,685,544 shares of common stock for $63,601,894 under the Sales Agreement pursuant to the Registration Statement, with 105,223,086 shares of common stock outstanding as of February 18, 2021. ($63.6M proceeds)

8-K filing: Synthetic Biologics, Inc. issued 1,851,149 shares of its common stock upon the conversion of 23,533 shares of its Series A Convertible Preferred Stock on February 9, 2021, and also reports that as of February 9, 2021, it has sold an aggregate of 36,496,555 shares of common stock under the Sales Agreement pursuant to the Registration Statement and had 72,685,015 shares of common stock outstanding.

8-K filing: Synthetic Biologics, Inc. issued 3,454,005 shares of its common stock upon the conversion of 47,398 shares of its Series A Convertible Preferred Stock on February 5, 2021.

8-K filing: Synthetic Biologics, Inc. updated information on its Registration Statement relating to the offer and sale of shares of its common stock through B. Riley Securities, Inc. As of February 3, 2021, the Company has sold an aggregate of 32,574,188 shares of common stock having an aggregate offering price of $30,348,066 under the Sales Agreement pursuant to the Registration Statement. ($30.35M proceeds)

8-K filing: Synthetic Biologics, Inc. issued 3,160,000 shares of its common stock upon conversion of 47,400 shares of its Series A Convertible Preferred Stock on January 29, 2021.

8-K filing: On January 19, 2021, Synthetic Biologics, Inc. reported the sale of 26,009,427 shares of common stock for $24,780,844 and outstanding shares of 53,669,733. ($24.78M proceeds)

8-K filing: Synthetic Biologics, Inc. reports the sale of 12,802,366 shares of common stock for $15,942,452 under an At Market Issuance Sales Agreement as of January 6, 2021, and has 36,954,708 shares of common stock outstanding. ($0.0M proceeds)

8-K filing: On November 17, 2020, Synthetic Biologics, Inc. reported the sale of an aggregate of 3,545,831 shares of common stock (on a post 2018 split basis) having an aggregate offering price of $12,496,747 under the At Market Issuance Sales Agreement. ($12.5M proceeds)

10-Q filing | 20.0M shares outstanding

10-Q filing | 19.4M shares outstanding

10-Q filing | 18.3M shares outstanding

10-K filing | 17.0M shares outstanding